Brief: Orexo Announces FDA Acceptance Of New Drug Application Filing For OX124
Nov 28 (Reuters) - Orexo AB ORX.ST :
* OREXO ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION
FILING
FOR OX124, A HIGH-DOSE RESCUE MEDICATION FOR OPIOID OVERDOSE
* PRESCRIPTION DRUG USER FEE ACT DATE (PDUFA) SET TO JULY
15, 2024
* IF APPROVED, US LAUNCH IS EXPECTED TO BE INITIATED LATE
2024
Source text for Eikon: ID:nWkrtRfMX
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens